The Precision Health Initiative is conducted by Genuity Science. Learn more about our recent restructure here.

Why the WuXi NextCODE split makes strategic sense for the multinational genomics company

WuXi NextCODE’s move to split its China business from operations in the U.S. and Europe seems like the best path forward for both entities, as each faces tightening regulations that restrict the flow of genomic data across international borders.

The U.S.-headquartered genomics company announced restructuring plans on June 23 that would integrate its U.S., Ireland and Icelandic operations under a renamed entity called Genuity Science, while cutting ties from the Chinese operations of WuXi NextCODE Genomics Inc. in Shanghai. Both entities integrate genomics across the drug development continuum with applications ranging from target identification to patient stratification.

See the full article.